Akèy › Myelom Miltip › Washington › Tacoma
Etid klinik pou Myelom Miltip nan Tacoma, WA
13 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Tacoma (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Ap rekriteFaz 3
- Study Site 103, Tacoma
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, Puyallup · 8 mi lwen
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- NorthWest Medical Specialties, PLLC, Tacoma
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Ap rekriteFaz 4
- Northwest Medical Specialties, PLLC, Tacoma
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 3
- NorthWest Medical Specialties, PLLC, Tacoma
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 1
- American Oncology Network Vista Oncology Division / Physician partner associate, Olympia · 26 mi lwen
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Northwest Medical Specialties, Tacoma
- Northwest Medical Specialties, Gig Harbor · 8 mi lwen
- Northwest Medical Specialties, Puyallup · 8 mi lwen
- ak 1 plis
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1/2
- Northwest Medical Specialties Tacoma /ID# 272506, Tacoma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Northwest Medical Specialties, Tacoma
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, Puyallup · 8 mi lwen
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Northwest Medical Specialties Tacoma /ID# 267117, Tacoma
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Ap rekriteFaz 3
- Providence Regional Cancer System-Yelm, Yelm · 23 mi lwen
- Providence Regional Cancer System-Lacey, Lacey · 23 mi lwen
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Ap rekriteFaz 3
- GSK Investigational Site, Puyallup · 8 mi lwen
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Tacoma
- Kansè Poumon ki pa ti selil20 etid
- Kansè nan tete18 etid
- Kolit Ulseratif15 etid
- Kansè pwostat11 etid
- Maladi Crohn11 etid
- Kansè Metastatik9 etid
- Kansè kolorektal9 etid
- Melanom7 etid
- Kansè ovè7 etid
- Kansè (tout kalite)6 etid
- Kansè pankreyas6 etid
- Obèsite6 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.